Two-stage resection of the large intestine with deep peritoneal stitching

1927 ◽  
Vol 23 (2) ◽  
pp. 246-246
Author(s):  
I. Tsimkhes
Keyword(s):  
Colorectal Cancer ◽  
Large Intestine ◽  
Abdominal Cavity ◽  
Parietal Peritoneum ◽  
Abdominal Wound ◽  
Two Stage ◽  
Wound Area

For almost 20 years, in colorectal cancer, where the affected loop and adjacent healthy sections of the large intestine cannot be sufficiently mobilized, even after separation and ligation of the mesentery, the author has been cutting off the parietal peritoneum with fascia of the abdominal wound area and plunging them as deeply into the abdominal cavity as possible.

scholarly journals Multiple peritoneal dissemination of T2 colorectal cancer without lymph node metastases: a case report

2020 ◽  
Vol 2020 (7) ◽  
Author(s):  
Yosuke Namba ◽  
Yuzo Hirata ◽  
Shoichiro Mukai ◽  
Toshihiro Nishida ◽  
Syo Ishikawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Peritoneal Dissemination ◽  
Abdominal Cavity ◽  
Muscularis Propria ◽  
Ileocecal Resection ◽  
Pathology Report ◽  
Ascending Colon ◽  
Node Metastases

Abstract Most cases of peritoneal dissemination of colorectal cancers are from T3 or T4 tumors. A 61-year-old woman was admitted for examination of a positive fecal occult blood test. Colonoscopy showed an ascending colon tumor that was diagnosed as an adenocarcinoma with massive submucosal invasion. Imaging modality revealed numerous nodules throughout the abdominal cavity. Peritoneal dissemination of the ascending colon or ovarian cancer and pseudomyxoma peritonei were considered in the preoperative differential diagnoses, and laparoscopic ileocecal resection was performed. Intraperitoneal observation revealed numerous white nodules in the peritoneum, omentum and Douglas fossa. Both the nodules and tumor were diagnosed as mucinous carcinoma based on a pathology report. The tumor invasion depth was limited to muscularis propria, and no regional lymph node metastasis was detected. Peritoneal dissemination of the ascending colon cancer was considered. We report a rare case of multiple peritoneal dissemination of T2 colorectal cancer without lymph node metastases.

Sectio alta transperitonealis in 2 doses

1930 ◽  
Vol 26 (3) ◽  
pp. 327-327
Author(s):  
F. Schewket
Keyword(s):  
Abdominal Cavity ◽  
Parietal Peritoneum ◽  
Layer By Layer ◽  
Bladder Stones

Abstracts. Surgery. Sectio alta transperitonealis in 2 divided doses. Feridum Schewket (Zentrbl. F. Chir. 1930, No. 2) successfully removed bladder stones in 2 cases, suturing the bladder to the parietal peritoneum after opening the abdominal cavity, and after 24 hours opened the bladder, removed the stone and then stitched up the wound layer by layer tightly. After 12 days, his patients (12 and 8 year old boys) recovered.

scholarly journals Experimental research on the origin of adhesions in the abdominal cavity after operations

2020 ◽  
Vol 5 (5) ◽  
pp. 504-507
Author(s):  
N. Aleksenko
Keyword(s):  
Experimental Research ◽  
Inflammatory Process ◽  
Abdominal Cavity ◽  
Abdominal Wound ◽  
Middle Line ◽  
Clinical Observations

Fusion of intestines and omentum after surgery, mainly with an abdominal wound, is a frequent phenomenon, proven by a number of clinical observations during repeated operations in the same subjects. Meanwhile, the question of the reasons for such a phenomenon, despite attempts to experimentally resolve it (Snger, Dembowski, Kelterborn), remains open to this day. According to the opinion of the last mentioned authors, the main cause of adhesions in the abdominal cavity after operations is infection, the accretion of the omentum to the middle line is caused by the release of air and the local inflammatory process; further - sloughing of the epithelium and scars of the peritoneum in uncomplicated cases do not give adhesions, ligatures in the abdominal cavity for the most part also do not cause adhesions, but show a tendency to encapsulate.

Long-Term Results of Two-Stage Hepatectomy for Irresectable Colorectal Cancer Liver Metastases

2008 ◽  
Vol 248 (6) ◽  
pp. 994-1005 ◽  
Author(s):  
Dennis A. Wicherts ◽  
Rafael Miller ◽  
Robbert J. de Haas ◽  
Georgia Bitsakou ◽  
Eric Vibert ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Long Term Results ◽  
Two Stage ◽  
Colorectal Cancer Liver Metastases

scholarly journals Cytoreductive surgery and HIPEC in colorectal cancer—did we get hold of the wrong end of the stick?

2020 ◽  
Vol 13 (4) ◽  
pp. 434-439 ◽  
Author(s):  
Can Yurttas ◽  
Oliver M. Fisher ◽  
Delia Cortés-Guiral ◽  
Sebastian P. Haen ◽  
Ingmar Königsrainer ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cytoreductive Surgery ◽  
Treatment Approach ◽  
Abdominal Cavity ◽  
Basic Research ◽  
Surgical Interventions ◽  
Randomized Controlled ◽  
Surgical Expertise ◽  
Harmful Effects ◽  
Shed Light

SummaryCytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are a multimodal treatment approach combining surgical interventions of varying extent with administration of heated cytostatic drugs flushed through the abdominal cavity. Hitherto, this treatment has been popular for peritoneal metastasis (PM), e.g. from colorectal cancer (CRC). Recent randomized controlled trials (RCT) question the benefit of HIPEC in its present form for CRC treatment and raise fundamental issues, eliciting discussions and expert statements regarding HIPEC relevance and interpretation of these results. Unfortunately, such discussions have to remain uninformed, due to the lacking publication of crucial peer reviewed RCT results. Novel basic research aware of HIPEC futility suggests there may be systematic limitations. Innovative modelling approaches for HIPEC may shed light on the reasons for therapeutic failure of frequently used drugs and may lead the way to select better alternatives and/or more rational approaches for the design of HIPEC procedures (e.g. regarding exposure time or temperature). Available evidence strongly supports the notion that CRS is the mainstay for the treatment effects observed in PM from CRC. Unfortunately, HIPEC has become a surrogate for surgical expertise in the field and optimal surgery may therefore outweigh the potentially harmful effects of HIPEC treatment, particularly in lieu of modern systemic chemotherapies. The current situation which frequently is assumed to be deadlocked should be regarded as a challenge to investigate HIPEC with well-designed prospective clinical trials, potentially even constituting an opportunity for introducing innovative trial designs that solve the multifaceted issues of a very heterogeneous treatment approach.

Recombinant adeno-viral human p53 gene combined with FOLFOX4 in the treatment of advanced colorectal cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14036-e14036
Author(s):  
Zhong-guo Zhang
Keyword(s):  
Colorectal Cancer ◽  
Adverse Events ◽  
Saline Solution ◽  
Advanced Colorectal Cancer ◽  
Recurrent Disease ◽  
Abdominal Cavity ◽  
Combined Treatment ◽  
P53 Gene ◽  
Serious Adverse Events

e14036 Background: Metastatic or recurrent colorectal cancers generally become unresectable and will not respond to radio- or chemo-therapy. Studies showed that p53 has a synergic effect with radio- or chemotherapy. This study is to determine the efficacy and safety of recombinant adenoviral human p53 gene (rAd-p53) combined with standard FOLFOX4 regimen in treatment of advanced colorectal cancer. Methods: From July 2008 to Dec. 2011, 56 patients with an advanced colorectal cancer or local recurrent disease were treated with rAd-p53 and standard FOLFOX4 regimen. For local tumor, 1-4×1012 viral particles (VP) of rAd-p53 diluted into 5 ml of saline solution was injected into tumor at multiple directions, once a week for 6 weeks. If tumor spreading into abdominal cavity, 4×1012 VPs diluted in 500 ml of saline solution were injected inraperitoneally, twice in 2 weeks. If having lung or liver metastasis, 2×1012 VPs diluted into 100 ml of saline solution were given intravenously twice in 2 weeks. Three days after the first gene therapy, the standard FOLFOX4 regimen was given for six cycles. Results: The follow-up time was 3~38 months with a median of 19.5 months. Among these patients, 8 (14.3%) patients were assessed as complete response, 31 (55.4%) as partial response and 11 (19.6%) as stable disease. After the combined treatment, a radical resection was successfully performed in 18 cases with local recurrent disease. All these patients were still alive at the last follow-up. Common adverse events were 38.4~40.5 oC self-limited fever, occurring in 86% patients. No serious adverse events were observed. Conclusions: rAd-p53 combined with FOLFOX4 is a safe and effective treatment for advanced colorectal cancer or local recurrent disease.

Sign in / Sign up

Export Citation Format

Share Document